<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Parkinsons Dis</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Parkinsons Dis</journal-id><journal-title-group><journal-title>NPJ Parkinson's Disease</journal-title></journal-title-group><issn pub-type="epub">2373-8057</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6941970</article-id><article-id pub-id-type="publisher-id">103</article-id><article-id pub-id-type="doi">10.1038/s41531-019-0103-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Parkinson&#x02019;s disease: proteinopathy or lipidopathy?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Fanning</surname><given-names>Saranna</given-names></name><address><email>sfanning2@bwh.harvard.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Selkoe</surname><given-names>Dennis</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6676-0107</contrib-id><name><surname>Dettmer</surname><given-names>Ulf</given-names></name><address><email>udettmer@bwh.harvard.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0378 8294</institution-id><institution-id institution-id-type="GRID">grid.62560.37</institution-id><institution>Ann Romney Center for Neurologic Diseases, Department of Neurology, </institution><institution>Brigham and Women&#x02019;s Hospital and Harvard Medical School, </institution></institution-wrap>Boston, MA 02115 USA </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>6</volume><elocation-id>3</elocation-id><history><date date-type="received"><day>7</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>2</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Lipids play a more significant role in Parkinson&#x02019;s disease and its related brain disorders than is currently recognized, supporting a &#x0201c;lipid cascade&#x0201d;. The 14&#x02009;kDa protein &#x003b1;-synuclein (&#x003b1;S) is strongly associated with Parkinson&#x02019;s disease (PD), dementia with Lewy bodies (DLB), other synucleinopathies such as multiple system atrophy, and even certain forms of Alzheimer&#x02019;s disease. Rigorously deciphering the biochemistry of &#x003b1;S in native systems is the key to developing treatments. &#x003b1;S is highly expressed in the brain, the second most lipid-rich organ, and has been proposed to be a lipid-binding protein that physiologically interacts with phospholipids and fatty acids (FAs). &#x003b1;S-rich cytoplasmic inclusions called Lewy bodies and Lewy neurites are the hallmark lesions of synucleinopathies. Excess &#x003b1;S&#x02013;membrane interactions may trigger proteinaceous &#x003b1;S aggregation by stimulating its primary nucleation. However, &#x003b1;S may also exert its toxicity prior to or independent of its self-aggregation, e.g., via excessive membrane interactions, which may be promoted by certain lipids and FAs. A complex &#x003b1;S-lipid landscape exists, which comprises both physiological and pathological states of &#x003b1;S. As novel insights about the composition of Lewy lesions occur, new lipid-related PD drug candidates emerge, and genome-wide association studies (GWAS) increasingly validate new hits in lipid-associated pathways, it seems timely to review our current knowledge of lipids in PD and consider the roles for these pathways in synucleinopathies.<fig id="Fig1"><label>Fig. 1</label><caption><title>&#x003b1;S&#x02009;&#x02194;&#x02009;lipid interplay: aspects of cellular &#x003b1;S homeostasis (blue oval), aspects of lipid homeostasis (green oval), and overlapping aspects.</title><p>Pathological states are labeled in red. Simplified schematic of both select &#x003b1;S and select lipid species. Several existing publications suggest &#x003b1;S effects on lipids and vice versa, as indicated by arrows. DG diglyceride, ER endoplasmic reticulum, FA fatty acid, LD, lipid droplet, TG triglyceride.</p></caption><graphic xlink:href="41531_2019_103_Fig1_HTML" id="d29e221"/></fig></p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Parkinson's disease</kwd><kwd>Cellular neuroscience</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">The 14&#x02009;kDa protein &#x003b1;-synuclein (&#x003b1;S) is strongly associated with Parkinson&#x02019;s disease (PD), dementia with Lewy bodies (DLB), other synucleinopathies such as multiple system atrophy, and even certain forms of Alzheimer&#x02019;s disease. Rigorously deciphering the biochemistry of &#x003b1;S in native systems is the key to developing treatments. &#x003b1;S is highly expressed in brain, the second most lipid-rich organ,<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> and has been proposed to be a lipid-binding protein that physiologically interacts with phospholipids<sup><xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref></sup> and fatty acids (FAs).<sup><xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref></sup> &#x003b1;S-rich cytoplasmic inclusions called Lewy bodies (LBs) and Lewy neurites are the hallmark lesions of synucleinopathies. Excess &#x003b1;S&#x02013;membrane interactions may trigger proteinaceous &#x003b1;S aggregation by stimulating its primary nucleation.<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> However, &#x003b1;S may also exert its toxicity prior to or independent of its self-aggregation, e.g., via excessive membrane interactions,<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup> which may be promoted by certain lipids and FAs. A complex &#x003b1;S-lipid landscape exists that comprises both physiological and pathological states of &#x003b1;S (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). As novel insights about the composition of Lewy lesions occur,<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> new lipid-related PD drug candidates emerge<sup><xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref></sup> and genome-wide association studies (GWAS) increasingly validate new hits in lipid-associated pathways,<sup><xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref></sup> it seems timely to review our current knowledge of lipids in PD and consider the roles for these pathways in synucleinopathies.</p></sec><sec id="Sec2"><title>&#x003b1;S transiently binds to lipid membranes physiologically</title><p id="Par3">Early biochemical characterization identified &#x003b1;S as soluble<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup> and brain extract fractionation showed only a weak association with synaptic vesicles,<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup> confirming immunogold-EM that had detected &#x003b1;S throughout cytoplasmic matrices in axon terminals.<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> Photobleaching microscopy also indicated that &#x003b1;S interacts only weakly with membranes of the nerve terminal and switches rapidly between the cytosol and membrane.<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup> The earliest characterizations of &#x003b1;S already suggested that binding of &#x003b1;S to membranes may occur via the formation of amphipathic helices mediated by an 11-amino acid repeat motif having the core consensus sequence KTKEGV.<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> This motif appears imperfectly six to nine times in the first two-thirds of the protein<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> (Fig. <xref rid="Fig2" ref-type="fig">2a&#x02013;c</xref>) and resembles lipid-binding domains often observed in apolipoproteins.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> &#x0201c;Cis&#x0201d; and &#x0201c;trans&#x0201d; factors mediate the transient &#x003b1;S&#x02013;membrane interaction when the N-terminal two-thirds of &#x003b1;S form an 11/3 helix (11 amino acids/three turns)<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> (Fig. <xref rid="Fig2" ref-type="fig">2d</xref>). Nonpolar amino acid residues in the hydrophobic half of the &#x003b1;S amphipathic helix &#x0201c;dip&#x0201d; into the membrane bilayer (~1&#x02013;5&#x02009;&#x000c5; below lipid head groups),<sup><xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref></sup> interacting with the lipid &#x0201c;tails&#x0201d; via van der Waals forces (Fig. <xref rid="Fig2" ref-type="fig">2d</xref>). Lysine residues (+) in the <underline>K</underline>T<underline>K</underline>EGV motifs interact with membrane lipid head groups (&#x02212;).<sup><xref ref-type="bibr" rid="CR41">41</xref></sup> On the &#x0201c;trans&#x0201d; side, vesicle membrane composition<sup><xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref></sup> and vesicle size affect &#x003b1;S binding: negatively charged head groups promote the interaction with lysine residues (see above) and small vesicles that exhibit &#x0201c;lipid packing defects&#x0201d; promote &#x003b1;S &#x0201c;insertion&#x0201d; into the membrane.<sup><xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup> The helix formation is only transient, not stable, because some nonpolar residues are found in the hydrophilic half of the helix and some polar residues interact with lipid bilayer, most importantly threonine residues (see Fig. <xref rid="Fig2" ref-type="fig">2d</xref>). This imperfect helix formation seems to underlie the transient nature of &#x003b1;S&#x02013;membrane binding.<sup><xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref></sup> A recent, elegant in vitro study suggests &#x003b1;S that comes off the membrane does not immediately lose its fold, but may actually retain it, and this may go hand-in-hand with native &#x003b1;S&#x02013;&#x003b1;S assembly.<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> The authors studied &#x003b1;S binding to small unilamellar vesicles composed of phosphatidylcholine (PC) with 13:0 fatty acyl side chains. Modulating &#x003b1;S binding via phase transitions of the vesicle lipids allowed the reconstitution of soluble helical &#x003b1;S species that behaved as multimers. These observations are in agreement with previous descriptions of soluble &#x003b1;S multimers (and tetramers might be the most abundant species among them).<sup><xref ref-type="bibr" rid="CR52">52</xref>&#x02013;<xref ref-type="bibr" rid="CR60">60</xref></sup> Membrane-associated &#x003b1;S multimers, however, have also been described, e.g., in the context of mediating SNARE complex assembly<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> and vesicle clustering.<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> Figure <xref rid="Fig2" ref-type="fig">2d</xref> illustrates a model of dynamic cellular &#x003b1;S behavior in health, centered on the idea of membrane-assisted, transient &#x003b1;S helical folding and resultant multimer formation.<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> Research from our department and other labs suggests that perturbations of a complex equilibrium between monomers and multimers, as well as between free and membrane-bound states, may represent an initial biochemical change that eventually leads to &#x003b1;S- and membrane-rich cytoplasmic inclusions (LBs/neurites) and progressive neurotoxicity.<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR63">63</xref>,<xref ref-type="bibr" rid="CR64">64</xref></sup><fig id="Fig2"><label>Fig. 2</label><caption><title>Electrostatic and hydrophobic interactions govern transient &#x003b1;S membrane binding.</title><p><bold>a</bold> Amino acid sequence of human wt &#x003b1;S; residues that fully conform to the core repeat motif &#x0201c;KTKEGV&#x0201d; are highlighted in gray. <bold>b</bold> Amino acid sequence of human wt &#x003b1;S displayed by aligning the KTKEGV motifs. <bold>c</bold> Analogous to <bold>b</bold>, color-coded residues: black&#x02009;=&#x02009;uncharged, red&#x02009;=&#x02009;negatively charged, dark blue&#x02009;=&#x02009;positively charged, light blue&#x02009;=&#x02009;histidine, and purple&#x02009;=&#x02009;uncharged and polar. <bold>d</bold> Color-coded schematic of repeats 1&#x02013;7 (omitting &#x0201c;ATVA&#x0201d; between repeats 4 and 5) in an 11/3 helical wheel, embedded in the outer leaflet of a lipid membrane. <bold>e</bold> Simplified schematics of membrane-induced &#x003b1;S helices: &#x003b1;S wt as well as 3&#x02009;K (amplified E46K) and KLK (engineered highly hydrophobic). Top: wt. Middle: a proposed increased electrostatic interaction between excess positive charges of the lysines (highlighted in yellow) and phospholipid head groups is indicated by a blue line. Bottom: the KLK variant is stabilized by excess hydrophobicity in the hydrophobic half of the amphipathic helix, highlighted in yellow.</p></caption><graphic xlink:href="41531_2019_103_Fig2_HTML" id="d29e441"/></fig></p></sec><sec id="Sec3"><title>&#x003b1;S cytotoxicity: excess membrane binding vs. fibrillar aggregation</title><p id="Par4">The structure of &#x003b1;S suggests that transient &#x003b1;S&#x02013;membrane interactions could be stabilized biochemically by either amplifying the electrostatic interaction between positive lysines in &#x003b1;S and negative lipid head groups (e.g., via the engineered &#x0201c;3K&#x0201d; &#x003b1;S mutant) or by increasing the hydrophobicity in the lower, membrane-inserted half of the &#x003b1;S amphipathic helix (e.g., via the engineered &#x0201c;KLK&#x0201d; &#x003b1;S mutant) (Fig. <xref rid="Fig2" ref-type="fig">2e</xref>). We have found that such membrane-enriched mutants of &#x003b1;S decrease multimers and lead to acute toxicity and inclusion formation when expressed in cultured cells. The resulting inclusions, however, were shown by electron microscopy (EM) not to be overtly fibrillar but rather rich in &#x003b1;S-decorated vesicles.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> This experimental finding was seemingly at odds with the original isolation of filamentous aggregates from LBs that were &#x003b1;S-positive by immunogold electron microscopy.<sup><xref ref-type="bibr" rid="CR65">65</xref>,<xref ref-type="bibr" rid="CR66">66</xref></sup> However, it may be consistent with an experimental study of random &#x003b1;S point mutants that assessed their fibrillization in vitro (test tubes) and in living yeast.<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> Here, in vitro fibrillization rate and in vivo yeast toxicity did not correlate, suggesting that fibrillization is not necessary for &#x003b1;S-induced yeast toxicity. A second screen in a library of several thousand &#x003b1;S-mutant yeast clones identified 25 non-cytotoxic &#x003b1;S sequence variants.<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> Most of these sequence variants contained an &#x003b1;S mutation to either proline (P) or glutamic acid (E), which abnormally decreased &#x003b1;S membrane binding relative to wild-type (wt) &#x003b1;S. The authors hypothesized that &#x003b1;S cytotoxicity in yeast is caused by the protein binding to membranes at levels sufficient to nonspecifically disrupt membrane homeostasis. Subsequent yeast studies helped further characterize this membrane-associated toxicity: wt human &#x003b1;S expression in yeast (which lack an &#x003b1;S gene) led to vesicle clustering/aggregation<sup><xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref></sup> and vesicle-trafficking defects.<sup><xref ref-type="bibr" rid="CR69">69</xref></sup> &#x0201c;Amyloid&#x0201d; was typically not obvious (see also review by Jarosz and Khurana<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>), even though at least one study also reported fibrillar aggregates upon &#x003b1;S expression in yeast.<sup><xref ref-type="bibr" rid="CR71">71</xref></sup> The relevance of the vesicle-related observations beyond yeast was supported when similar trafficking defects were described in &#x003b1;S A53T and &#x003b1;S triplication iPSC-derived human neurons.<sup><xref ref-type="bibr" rid="CR72">72</xref></sup> Nonetheless, the putative lack of amyloid-type &#x003b1;S aggregates in yeast was viewed critically by some investigators, because filaments of &#x003b1;S had long been considered the hallmark of human Lewy cytopathology, calling into question the relevance of the &#x003b1;S yeast model. A debate thus arose between those that only accepted amyloid-type &#x003b1;S fibrillar aggregation as disease relevant and others who were open to other forms of &#x003b1;S misfolding, including membrane-associated aggregation (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Although the former group could generally rely on the support of neuropathologists, the literature on human LBs has actually provided some evidence of membrane-associated &#x003b1;S aggregation.<fig id="Fig3"><label>Fig. 3</label><caption><title>Contrasting &#x003b1;S fibrillar (&#x0201c;amyloid&#x0201d;) and (vesicle) membrane/lipid-rich aggregation forms.</title><p>They are not mutually exclusive. Membranous aggregates could, e.g., be precursors of fibrillar aggregates.</p></caption><graphic xlink:href="41531_2019_103_Fig3_HTML" id="d29e507"/></fig></p></sec><sec id="Sec4"><title>Membrane-associated &#x003b1;S aggregation in Lewy pathology</title><p id="Par5">Early descriptions of human Lewy cytopathology in the 1960s and 70s reported filament-rich regions in LBs but also some vesicle/membrane components<sup><xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR74">74</xref></sup> and occasional reports in the 1980s and 90s confirmed this observation.<sup><xref ref-type="bibr" rid="CR75">75</xref>&#x02013;<xref ref-type="bibr" rid="CR77">77</xref></sup> Nonetheless, the acceptance of this insight and its impact on conceptualizing PD pathogenesis and developing PD biomarkers and drugs has been limited so far. This situation may change after a striking recent publication: a detailed analysis<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> of PD brain tissue by correlative light and electron microscopy, a technique that allows immunohistological and EM ultrastructural analysis of the same lesions. The authors found that the majority of human LBs consisted of &#x003b1;S intermingled with clusters of various membranous structures or components (Fig. <xref rid="Fig4" ref-type="fig">4</xref>, right). Of special significance, the authors identified in the core of LBs various vesicle clusters that were coated with high local concentrations of non-fibrillar &#x003b1;S. Surprisingly, only about 20% of all LBs/LNs had large amyloid fibrils (at least 5&#x02009;nm diameter, at least 25&#x02009;nm in length; smaller structures were likely not detectable with the method) associated with them, indicating that amyloid-type &#x003b1;S aggregation is not as integral or required a part of PD cytopathology as formerly believed. Raman scattering and infrared spectroscopy showed that the LB core comprised large amounts of lipids, most importantly sphingomyelin and PC, as determined by mass spectrometry. These striking new insights raise the question of why these features of human LBs were apparently overlooked in the past. As the authors point out, the short postmortem intervals of their cases and the special tissue preservation methods they applied may be responsible. Traditional LB analyses (e.g., see ref. <sup><xref ref-type="bibr" rid="CR78">78</xref></sup>) have largely relied on immunohistochemical staining at the light microscopic level, providing limited resolution.<sup><xref ref-type="bibr" rid="CR79">79</xref></sup> Thus, a bias might have been created in the past for areas that showed the expected rod-like or fibrous structures (see a commentary by Bartels<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>). The important new findings of Shahmoradian et al.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> are based on state-of-the-art imaging techniques and, if confirmed by others, have the potential to change the ways in which we conceptualize and model PD pathogenesis and design therapeutics.<fig id="Fig4"><label>Fig. 4</label><caption><title>&#x003b1;S membrane-associated aggregation in LBs and models thereof.</title><p><bold>a</bold> Vesicle-rich membranous &#x003b1;S aggregation in the &#x003b1;S::GFP expression model in yeast. Insert: immunogold staining for &#x003b1;S. Reprinted by permission from the National Academy of Sciences, USA<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>. <bold>b</bold> Vesicle- and tubule-rich membranous &#x003b1;S aggregation in the &#x003b1;S 3K neuroblastoma cell model. Reprinted from Dettmer et al.<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> (CC-BY license). <bold>c</bold> Vesicle/membrane/lipid-rich &#x003b1;S aggregation in human Lewy bodies. Reprinted by permission from the Springer Publishing Group.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup></p></caption><graphic xlink:href="41531_2019_103_Fig4_HTML" id="d29e580"/></fig></p></sec><sec id="Sec5"><title>Membrane-associated aggregation in cellular models of &#x003b1;S dyshomeostasis</title><p id="Par6">The proposed lipid vesicle-rich clusters within human LBs are reminiscent of the effects of expressing human &#x003b1;S at relatively high concentrations in <italic>Saccharomyces cerevisiae</italic> (see above). The &#x003b1;S inclusions in yeast had initially been interpreted in light micrographs as proteinaceous aggregates. Gitler et al.,<sup><xref ref-type="bibr" rid="CR68">68</xref></sup> however, provided ultrastructural evidence that &#x003b1;S accumulations in yeast were not comprised of fibrils but rather were clusters of many vesicles (Fig. <xref rid="Fig4" ref-type="fig">4</xref>, left), and this was confirmed by another publication.<sup><xref ref-type="bibr" rid="CR67">67</xref></sup> Similarly, it was observed in yeast that accumulation of undocked vesicles coalesce into massive vesicle clusters in an &#x003b1;S dose-dependent manner.<sup><xref ref-type="bibr" rid="CR68">68</xref></sup> By immunofluoresence microscopy and immuno-EM, these non-filamentous &#x003b1;S inclusions in yeast were associated with vesicle markers of diverse subcellular origin (endosomes, Golgi, lysosomes). In contrast to yeast, mammalian neural cells expressing very high levels of wt, or even familial PD (fPD) single-mutant &#x003b1;S (e.g., E46K), may not readily show discrete &#x003b1;S inclusion formation (e.g., see ref. <sup><xref ref-type="bibr" rid="CR59">59</xref></sup>). In an HEK293 model, aggregation propensity of &#x003b1;S was shown to be exacerbated by fPD mutants A30P, A53T, and E46K.<sup><xref ref-type="bibr" rid="CR80">80</xref></sup> fPD mutants A53T, A30P, E46K, H50Q, and G51D were found to have the same oligomerization propensity but differing inclusion formation in a similar HEK293 model.<sup><xref ref-type="bibr" rid="CR81">81</xref></sup> The exact nature of these aggregates/inclusions as well as a possible cell-type dependence of the observed inclusions will require further analysis. It is important to mention that the known fPD-linked aS point mutations have diverging effects on membrane binding: A30P binds membranes less, E46K binds more strongly, and this may indicate that the initial pathways leading to toxicity may differ between mutants (see review<sup><xref ref-type="bibr" rid="CR50">50</xref></sup> for further details). Indeed, the degree to which the protein binds membranes in mammalian models seems to be recapitulated in yeast models of &#x003b1;S toxicity, e.g., &#x003b1;S A53T was shown to localize to (plasma) membranes, whereas A30P remained cytoplasmic, recapitulating the poor membrane binding nature of A30P reported in many models.<sup><xref ref-type="bibr" rid="CR82">82</xref></sup> To further elucidate the relationship between &#x003b1;S membrane binding and aggregation/toxicity, engineered &#x003b1;S mutations may prove to be useful tools. Certain engineered mutations in the &#x003b1;S KTKEGV motifs that decrease the cellular multimer:monomer ratio increase the interactions of the excess &#x003b1;S monomers with membranes Such mutations include &#x003b1;S &#x0201c;3K&#x0201d; (E35K&#x02009;+&#x02009;E46K&#x02009;+&#x02009;E61K),<sup><xref ref-type="bibr" rid="CR59">59</xref></sup> an amplification of the familial PD-causing E46K (Fig. <xref rid="Fig2" ref-type="fig">2e</xref>) or &#x0201c;KLK&#x0201d; (T12L&#x02009;+&#x02009;T23L&#x02009;+&#x02009;T34L&#x02009;+&#x02009;T45L&#x02009;+&#x02009;T60L&#x02009;+&#x02009;T71L&#x02009;+&#x02009;T82L; Fig. <xref rid="Fig2" ref-type="fig">2e</xref>).<sup><xref ref-type="bibr" rid="CR64">64</xref></sup> These exaggerated, membrane-enriched mutations have provided evidence that the vesicle-clustering property of human &#x003b1;S is not unique to yeast but can also be achieved in the time course of &#x003b1;S expression in cultured mammalian neural cells (Fig. <xref rid="Fig4" ref-type="fig">4</xref>, middle). In this context, it is important to note that the trafficking and clustering of membrane vesicles within synaptic terminals has been suggested to be a normal function of &#x003b1;S (reviewed in ref.; <sup><xref ref-type="bibr" rid="CR83">83</xref></sup> see also a recent review on the physiological role of &#x003b1;S and its relationship with PD<sup><xref ref-type="bibr" rid="CR84">84</xref></sup>). This raises the possibility that the abnormal vesicle clustering seen in &#x003b1;S-expressing yeast and in the vesicle-accumulating KTKEGV motif mutants represent a form of excessive &#x003b1;S function (a &#x0201c;toxic gain-of-function&#x0201d;). Interestingly, isolated monomeric, but not multimeric, &#x003b1;S was shown to interact with membranes in the test tube (presumably via helix formation, as the folding-deficient A30P did not interact), leading to membrane remodeling and tubulation.<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> Intact-cell crosslinking of neurons expressing inclusion-forming &#x003b1;S KTKEGV variants such as &#x0201c;3K&#x0201d; and &#x0201c;KLK&#x0201d; (Fig. <xref rid="Fig2" ref-type="fig">2e</xref>) suggests that &#x003b1;S in the membrane-rich inclusions may be principally monomeric. This raises the question of the nature of &#x003b1;S molecules in the vesicle-rich inclusions: are they amphipathic helices, the species that was shown to form at vesicles? Are they unfolded? Or are they early-stage &#x003b2;-sheet oligomers undetectable by crosslinking or yellow fluorescent protein (YFP) complementation? The first scenario, which we favor, would be most provocative, because the field of protein misfolding diseases is used to the dichotomy &#x0201c;helical fold&#x02009;=&#x02009;good, &#x003b2;-sheet&#x02009;=&#x02009;bad&#x0201d;.</p></sec><sec id="Sec6"><title>Is there a bidirectional interplay between &#x003b1;S and lipids?</title><p id="Par7">In addition to altering vesicle trafficking, expressing &#x003b1;S in yeast was shown to promote lipid droplet (LD) formation.<sup><xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR85">85</xref></sup> Changes in LD content and distribution have been associated with &#x003b1;S toxicity and membrane-trafficking defects in yeast and mammals (reviewed in ref. <sup><xref ref-type="bibr" rid="CR86">86</xref></sup>). Wt &#x003b1;S in mammalian cells has been proposed to bind to LDs<sup><xref ref-type="bibr" rid="CR85">85</xref></sup> and this binding propensity may be amplified by certain natural (E46K) or engineered (3K) KTKEGV mutants, which accumulate on membranes; the resultant cytoplasmic vesicle aggregates are often in the vicinity of LDs (see Figs 2 and 3 in ref. <sup><xref ref-type="bibr" rid="CR12">12</xref></sup>). Moreover, it was recently reported that &#x003b1;S expression in yeast and &#x003b1;S excess in rodent neurons or induced pluripotent stem cell (iPSC)-derived human neurons lead to marked alterations in lipid profiles, including increases in neutral lipids.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> Among FAs, oleic acid (OA) was found to be specifically elevated in response to excess &#x003b1;S monomers.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> Strikingly, reciprocal effects were also seen in this<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> and a related<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> study: lowering the enzymatic formation of monounsaturated FAs (MUFAs; e.g., OA) appeared to benefit &#x003b1;S biochemistry; it increased physiological &#x003b1;S multimerization, increased &#x003b1;S solubility, and decreased serine 129 phosphorylation. In contrast, conditioning cells with MUFAs had the opposite effects. These observations align in part with earlier work, demonstrating pathological &#x003b1;S oligomer accumulation upon conditioning cultured neural cells with polyunsaturated FAs (PUFAs).<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> The proposed &#x003b1;S-OA interplay is consistent with a scenario in which excess &#x003b1;S, in particular membrane-associated &#x003b1;S monomers, leads to an increase in MUFA levels, which in turn render &#x003b1;S more neurotoxic (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). Such a model is reminiscent of a &#x0201c;bidirectional pathogenic loop&#x0201d; that had been proposed for another cellular lipid, glucocerebrosidase (GCase), and &#x003b1;S<sup><xref ref-type="bibr" rid="CR87">87</xref></sup> (see below). A novel therapeutic strategy emerging from the work just summarized as follows: inhibiting the rate-limiting enzyme in the biosynthesis of MUFAs, stearoyl-CoA desaturase (SCD). This approach, which emerged simultaneously from another group based on unbiased compound screens in &#x003b1;S-expressing yeast,<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> could potentially (a) neutralize the upregulation of MUFAs by excess &#x003b1;S and (b) prevent detrimental structural changes in &#x003b1;S that are the consequence.<fig id="Fig5"><label>Fig. 5</label><caption><title>Indications for an &#x003b1;S&#x02009;&#x02194;&#x02009;OA bidirectional pathogenic loop.</title><p>&#x003b1;S excess leads to increased OA levels; increases in OA disrupt &#x003b1;S homeostasis leading to &#x003b1;S&#x02009;+&#x02009;vesicle clusters, vesicle-trafficking defects, and possibly &#x003b1;S aggregates. Inhibition of the rate-limiting enzyme in OA production, (SCD), promises to mitigate these pathogenic events.</p></caption><graphic xlink:href="41531_2019_103_Fig5_HTML" id="d29e726"/></fig></p></sec><sec id="Sec7"><title>Human genetics, patient samples, and experimental models link PD to lipid pathways</title><p id="Par8">The theory we emphasize here that lipid metabolism is central to &#x003b1;S homeostasis is particularly well supported by human genetic evidence that strongly suggest a key &#x003b1;S-lipid interplay (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) and a major role for certain lipids in modulating &#x003b1;S physiology and consequent toxicity in the brain.<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR88">88</xref></sup> This concept is in line with a systematic analysis of GWAS data and genetic networks that revealed lipid homeostasis as a common link between several processes involved in PD pathogenesis.<sup><xref ref-type="bibr" rid="CR89">89</xref></sup> GWAS have identified&#x02014;and postmortem brain analyses have confirmed&#x02014;several proteins that help regulate lipid metabolism, including LD biology, to be associated with PD. First and foremost, mutations in <italic>GBA</italic> (GCase), a key gene in glycolipid metabolism, significantly increase PD risk<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>&#x02014;and certain other genes in related pathways have also been implicated<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup> (see below). In addition, a diacylglycerol kinase, <italic>DGKQ</italic>, which controls diglyceride and phosphatidic acid content, emerged from several GWAS as a PD risk factor.<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref></sup> FA elongase 7, a determinant of fatty acyl side-chain length, and hence membrane composition and fluidity, was recently designated as another significant PD risk gene.<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR90">90</xref></sup> A phospholipase, <italic>PLA2G6</italic>, has been proposed to affect risk for PD and other brain diseases with &#x0201c;high brain iron&#x0201d;<sup><xref ref-type="bibr" rid="CR91">91</xref></sup>. Furthermore, seipin, an integral membrane protein localized at endoplasmic reticulum (ER)/LD contact sites and involved in LD biogenesis and maintenance,<sup><xref ref-type="bibr" rid="CR92">92</xref>,<xref ref-type="bibr" rid="CR93">93</xref></sup> may be differentially expressed in the brains of PD vs. control subjects.<sup><xref ref-type="bibr" rid="CR94">94</xref>,<xref ref-type="bibr" rid="CR95">95</xref></sup> These findings suggest phospholipid group and side-chain nature (dictated by FA type) play a critical role in PD, likely through &#x003b1;S interaction alterations. As far as non-cell-autonomous lipid homeostasis is concerned, variants in LRP10, a low-density lipoprotein receptor protein, were also reported be linked to PD dementia, DLB, and Lewy pathology,<sup><xref ref-type="bibr" rid="CR96">96</xref>,<xref ref-type="bibr" rid="CR97">97</xref></sup> but this remains controversial<sup><xref ref-type="bibr" rid="CR98">98</xref></sup> (LRP10 mutations have also been associated with increased Alzheimer&#x02019;s disease pathogenesis<sup><xref ref-type="bibr" rid="CR99">99</xref></sup>). Moreover, <italic>SREBF-1</italic>, a transcription factor that binds sterol regulatory element-1 and controls lipid homeostasis through sterol biosynthesis, has been identified in GWAS as a PD risk factor.<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> This finding, in addition to certain studies on statin use, suggests that sterol pathways in PD pathogenesis should not be ignored either.</p><p id="Par9">We hypothesize that the downstream effects of PD-relevant lipid alterations may involve changes in vesicle trafficking and vesicle function (lysosomes and synaptic vesicles in particular). Several known and emerging PD risk genes such as <italic>LRRK2</italic> (<italic>PARK8</italic>), <italic>RAB7</italic> (<italic>PARK16</italic>), <italic>VPS35</italic> (<italic>PARK17</italic>), <italic>SYNJ1</italic> (<italic>PARK20</italic>), <italic>VPS13C</italic> (<italic>PARK23</italic>), <italic>SYT11</italic>, and <italic>LIMP2</italic> (all reviewed in ref. <sup><xref ref-type="bibr" rid="CR86">86</xref></sup>) underline the relevance of vesicle trafficking and function in PD pathogenesis, and both are affected by lipid and/or &#x003b1;S alterations (further details are beyond the scope of this review). Focusing on putative upstream events and in the context of a possible &#x0201c;bidirectional interplay&#x0201d; between lipids and &#x003b1;S, the following paragraphs will summarize in some detail what genetics, patient samples, and model systems have taught us about how certain lipid species may alter &#x003b1;S biology&#x02014;and how they might be altered by &#x003b1;S.</p></sec><sec id="Sec8"><title>Glycolipids</title><p id="Par10">Although only slightly increasing disease risk (unlike <italic>SNCA</italic> and <italic>LRRK2</italic>), <italic>GBA</italic> (GCase) mutations are the most common risk factor for PD. Homozygous <italic>GBA</italic> mutations block proper sphingomyelin metabolism and cause Gaucher&#x02019;s disease, a developmental disorder characterized by lysosomal dysfunction. Heterozygous mutations (i.e., in Gaucher&#x02019;s carriers) have repeatedly been found to increase PD risk.<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup> A lack of GCase and the resultant glucosylceramide build-up promotes increased formation of abnormal oligomers of &#x003b1;S. In turn, elevated levels of these neurotoxic &#x003b1;S species result in reduced lysosomal GCase activity, which further stabilizes &#x003b1;S oligomers. Increasing lysosomal GCase, thereby decreasing &#x003b1;S oligomer formation, disrupts this pathogenic loop.<sup><xref ref-type="bibr" rid="CR87">87</xref></sup> By way of follow-up, the same group found that increasing lysosomal GCase activity in iPSC-derived dopamine neurons from patients with PD-associated <italic>GBA</italic> mutations reduced &#x003b1;S accumulation.<sup><xref ref-type="bibr" rid="CR100">100</xref></sup> In keeping with this concept, a study of the impact of <italic>GBA</italic> deficiency on &#x003b1;S homeostasis found that glycosphingolipid accumulation resulting from <italic>GBA</italic> loss-of-function decreased physiological &#x003b1;S multimers and increased the more aggregation-prone monomeric form. In accord, transfecting in wt <italic>GBA</italic> or applying the drug miglustat (which blocks a synthetic enzyme for glycosphingolipids) restored the physiological &#x003b1;S multimer:monomer ratio and decreased cytotoxicity.<sup><xref ref-type="bibr" rid="CR101">101</xref></sup> In mice with age-dependent reductions in GCase function, aberrant lipid association of &#x003b1;S (and tau) was found in a subset of Secretogranin II&#x02009;+&#x02009;large dense-core vesicles responsible for neurotransmission of dopamine and other monoamines.<sup><xref ref-type="bibr" rid="CR102">102</xref></sup> In addition to <italic>GBA</italic>, an association between mutations in the sphingomyelin phosphodiesterase <italic>SMPD1</italic> or in <italic>ASAH1</italic>, a lysosomal ceramidase, and PD were identified recently.<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> Moreover, deficiency in <italic>GALC</italic>, a lysosomal enzyme involved in the catabolism of galactosylceramide, may contribute to neuronal vulnerability in late-onset synucleinopathies.<sup><xref ref-type="bibr" rid="CR103">103</xref></sup></p></sec><sec id="Sec9"><title>Phosphatidylcholine</title><p id="Par11">PC is the most abundant phospholipid in cellular membranes.<sup><xref ref-type="bibr" rid="CR104">104</xref></sup> Decreased levels of PC containing the polyunsaturated fatty acyl side chains denoted 34:5, 36:5, and 38:5 were observed in the frontal cortex of PD brains.<sup><xref ref-type="bibr" rid="CR105">105</xref></sup> Similarly, PD visual cortex has been reported to have reductions in some PC species with polyunsaturated 34 and 36 carbon species, as well as decreases in 16:0, 18:0, 18:1, and 18:2 lyso-phosphatidylcholines (LPCs).<sup><xref ref-type="bibr" rid="CR106">106</xref></sup> In a study of PD patient plasma, PC 44:6 and 44:5 were increased and PC 35:6 was decreased.<sup><xref ref-type="bibr" rid="CR107">107</xref></sup> Such changes in PUFAs could be the consequence of &#x003b1;S accumulation on membranes, because trends for lower PC species were observed in yeast and rat cortical neuron models of &#x003b1;S excess.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> Treating rats with the dopaminergic neurotoxin 6-hydroxydopamine<sup><xref ref-type="bibr" rid="CR108">108</xref></sup> led to early (defined by the authors as preceding &#x0201c;full blown primary symptoms&#x0201d;) lipid changes in the substantia nigra (SN), with most PC species decreased. Exceptions were LPC 16:0 and LPC 18:1, which were increased. Interestingly, sex differences in lipid changes in PD patients have been observed: in one study, PC was significantly decreased in male patients only.<sup><xref ref-type="bibr" rid="CR109">109</xref></sup> An in vitro study, highlighting the importance of using native &#x003b1;S forms for studies, reported that PC affects conformation and aggregation of the <italic>N</italic>-acetylated form of &#x003b1;S, specifically that <italic>N</italic>-acetylation enhances binding to PC micelles and small unilamellar vesicles with high curvature.<sup><xref ref-type="bibr" rid="CR110">110</xref></sup></p></sec><sec id="Sec10"><title>Phosphatidylethanolamine</title><p id="Par12">Phosphatidylethanolamine (PE) is the next most abundant phospholipid after PC, comprising ~25% of total mammalian cellular phospholipids.<sup><xref ref-type="bibr" rid="CR111">111</xref></sup> In the brain ~45% of phospholipids are PE.<sup><xref ref-type="bibr" rid="CR112">112</xref></sup> Using magnetic resonance spectroscopic imaging, decreased PE (and PC) were observed in brains of early (Hoehn and Yahr stages I and II) PD patients but not in advanced (Hoehn and Yahr stages III and IV) cases.<sup><xref ref-type="bibr" rid="CR113">113</xref></sup> Decreases in multiple PE species (PE 34:2, 34:1, 36:4, 36:3, 36:1, 38:7, 38:6, 38:4, 40:6, 40:5, 40:4, 38p:7, and 40p:7) and Lysophosphatidylethanolamine species (16:0, 18:0, and 20:0p), particularly in the visual cortex, of PD patients relative to controls were reported.<sup><xref ref-type="bibr" rid="CR106">106</xref></sup> PE 36:3 was reduced in the amygdala and species 34:1, 36:3, and 36:2 were decreased in the anterior cortex cingulate of PD patients.<sup><xref ref-type="bibr" rid="CR106">106</xref></sup> PE 34:1 was found to be decreased in PD patient plasma.<sup><xref ref-type="bibr" rid="CR112">112</xref>,<xref ref-type="bibr" rid="CR113">113</xref></sup> A sex difference, as observed for PC above, was also noted for PE, with significantly lower PE levels in male PD patients (vs. controls) but not in females.<sup><xref ref-type="bibr" rid="CR109">109</xref></sup> The consequences of reduced PE for &#x003b1;S phenotypes have been analyzed by genetically reducing cellular PE content. Deletion of a phosphotidylserine (PS) decarboxylase (<italic>PSD1</italic>), which synthesizes PE from PS, increased cytoplasmic &#x003b1;S inclusion formation and enhanced &#x003b1;S toxicity in a yeast model. Importantly, dopaminergic neuron degeneration from expressing wt human &#x003b1;S was enhanced by PSD1 RNAi silencing in a <italic>Caenorhabditis elegans</italic> model of synucleinopathy, whereas supplementation with ethanolamine, a building block for PE synthesis, led to partial rescue.<sup><xref ref-type="bibr" rid="CR114">114</xref></sup> By way of follow-up, low levels of PE in the mitochondria resulted in ER stress and induced &#x003b1;S to form cytoplasmic foci in this model. Feeding with ethanolamine rescued this phenotype.<sup><xref ref-type="bibr" rid="CR115">115</xref></sup> Trends for lower levels of shorter chain PE species were observed in yeast expressing wt human &#x003b1;S, whereas longer-chained PE increased. Alterations in PE species appeared &#x003b1;S dose- and time-dependent in a rat cortical neuron model of &#x003b1;S accumulation.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup></p></sec><sec id="Sec11"><title>Phosphatidylinositol</title><p id="Par13">Phosphatidylinositol (PI) is the third or fourth most abundant phospholipid in cells (after PC, PE, and potentially PS).<sup><xref ref-type="bibr" rid="CR104">104</xref></sup> A study in rat brain identified PI 18:0/20:4 as the major PI species and stated that all major PI species contain at least one PUFA.<sup><xref ref-type="bibr" rid="CR116">116</xref></sup> PI decreases with age in both male and female mice, whereas lyso-PI decreases in females only.<sup><xref ref-type="bibr" rid="CR117">117</xref></sup> The PI total lipid class was shown to be significantly reduced in the SN of male PD patients relative to controls.<sup><xref ref-type="bibr" rid="CR109">109</xref></sup> Decreased PI, particularly saturated PI species, was observed in yeast expressing human &#x003b1;S, whereas rat and human cortical neuron models overexpressing &#x003b1;S trended to decreased PI also.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> Although not the most prominent phospholipid or lyso-phospholipid, changes in the visual cortex and amygdala included decreases in PI 38:5 and increases in PI 36:1, 38:3, and 40:4 in PD vs. control brain.<sup><xref ref-type="bibr" rid="CR106">106</xref></sup></p></sec><sec id="Sec12"><title>Phosphotidylserine</title><p id="Par14">Phosphotidylserine (PS) is a quantitatively minor membrane phospholipid that makes up 2&#x02013;10% of total phospholipids in mammalian cells.<sup><xref ref-type="bibr" rid="CR112">112</xref></sup> PS is an important precursor of mitochondrial PE, which is produced by the mitochondrial enzyme PS decarboxylase. As part of a study analyzing membrane phospholipid synthesis of the SN in PD vs. control brains, it was observed that such synthesis may increase during the course of PD development,<sup><xref ref-type="bibr" rid="CR118">118</xref></sup> suggesting increased PS, PE, and/or PC would be observed in PD patients. In this regard, increases in PD frontal cortex of specific PS species have been observed, namely PS with 36:1, 36:2, and 38:3 fatty acyl side chains. PS has also been suggested to play a role in regulating &#x003b1;S-facilitated synaptic vesicle docking by aiding SNARE complex formation.<sup><xref ref-type="bibr" rid="CR119">119</xref></sup> Lipid raft levels of PS were 36% higher in the brains of &#x0201c;incidental PD&#x0201d; patients (cases with brain stem LB pathology but devoid of motor symptoms), but not in typical PD brains, relative to controls.<sup><xref ref-type="bibr" rid="CR120">120</xref></sup></p></sec><sec id="Sec13"><title>Conclusions: proteinopathy vs. lipidopathy in PD and related brain diseases</title><p id="Par15">PD has been principally thought of heretofore as a classical &#x0201c;proteinopathy&#x0201d;&#x02014;a disease that is caused by the misfolding of a protein into &#x003b2;-sheet-rich fibrillar aggregates. In this scenario, neurons are typically thought to suffer from an imbalance between protein synthesis or folding and protein degradation, leading gradually to neuronal dysfunction and death. Both reduced<sup><xref ref-type="bibr" rid="CR63">63</xref></sup> and excess<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> &#x003b1;S&#x02013;membrane interactions, as well as interactions with certain FAs<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> have been discussed as potential triggers for toxic &#x003b1;S oligomerization and fibril formation, consistent with the concept of a &#x0201c;lipid-induced proteinopathy&#x0201d;. However, recent advances in LB analysis and PD modeling now provide evidence for the opposite sequence, i.e., synucleinopathies may be &#x0201c;protein-induced lipidopathies&#x0201d;. In this hypothesis, an imbalance in cellular lipid homeostasis is the actual neurotoxic process and &#x003b1;S dyshomeostasis (e.g., excess or reduced vesicle binding of &#x003b1;S associated with fibrillar aggregation) is the trigger. Perhaps it is more sensible not to propose a dichotomy: PD and related human synucleinopathies may simultaneously be proteinopathies and lipidopathies, and a vicious cycle of dyshomeostasis in protein folding and lipid metabolism might be triggered by early and subtle changes in either lipid or protein handling (the initial alteration may differ from case to case).</p><p id="Par16">Although support for all three scenarios can be found in previous and recent research, the question becomes whether it is important to put a conceptual label on the disease or more scientifically relevant to keep both protein and lipid alterations in mind when exploring new ideas for therapeutics. As an example, the inhibition of SCD, a new therapeutic target, may indeed both counteract changes in lipid metabolism that are triggered by &#x003b1;S accumulation and prevent any negative feedback of these lipid changes on &#x003b1;S structure.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> Regulation of FAs other than MUFAs may also prove valuable, given the report that arachidonic acid (20:4) promotes the formation of helical &#x003b1;S multimers, and these may resist fibril formation and result in reduced neuronal damage.<sup><xref ref-type="bibr" rid="CR60">60</xref></sup></p><p id="Par17">The emerging evidence that &#x003b1;S accumulation in LBs may not solely be fibrillar as traditionally assumed has several important implications. First, the popular &#x0201c;PFF&#x0201d; model of &#x003b1;S fibrillization and proteotoxicity<sup><xref ref-type="bibr" rid="CR121">121</xref>,<xref ref-type="bibr" rid="CR122">122</xref></sup> may have to be rethought and complemented with models of intracellular membrane-mediated &#x003b1;S aggregation such as the &#x003b1;S &#x0201c;3K&#x0201d; model that was developed in cultured cells<sup><xref ref-type="bibr" rid="CR59">59</xref></sup> and then shown in transgenic mice to cause PD-like phenotypes.<sup><xref ref-type="bibr" rid="CR123">123</xref></sup> Second, positron emission topography tracers for synucleinopathies may have to be designed differently than attempted thus far, taking into account the protein&#x02019;s excess on cellular membranes in a yet undefined conformation. Third, drugs that alter lipid and FA homeostasis in addition to SCD inhibitors may become promising targets.<sup><xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref></sup> Fourth, the common assumption that proteinopathy means amyloid aggregation may have to be modified in the case of &#x003b1;S in PD and DLB. From these and other considerations, a new model is emerging in which &#x003b1;S &#x0201c;misfolding&#x0201d; in the cell can occur on several levels. Just an excess amount of the wt &#x003b1;S monomer that normally interacts with vesicles, i.e., which forms physiological amphipathic helices, may already have to be considered a type of &#x0201c;misfolding&#x0201d;. Thus, excess membrane-associated &#x003b1;S may be cytotoxic and disease relevant in the absence of actual &#x003b2;-sheet-rich fibrillar aggregation. A progression to &#x003b2;-sheet-rich fibrillar aggregates may confer further detriment, but it might also be temporarily beneficial by sequestering &#x003b1;S monomers away from membrane vesicles, thereby mitigating negative effects on vesicle trafficking. The recently published &#x003b1;S &#x0201c;3K&#x0201d; mouse model that exhibits a pronounced neurodegenerative and movement disorder phenotype indeed developed vesicle-rich &#x003b1;S&#x02009;+&#x02009;aggregation in young animals, whereas older animals seemed to display occasional &#x0201c;classical&#x0201d; filament-rich amyloid aggregates.<sup><xref ref-type="bibr" rid="CR123">123</xref></sup> This finding could indicate that vesicle clustering is potentially an early event in LB formation, whereas fibrillar aggregates are characteristic of more mature inclusions. Related to these considerations may be the question of the nature of the so-called &#x0201c;pale bodies&#x0201d; of &#x003b1;S aggregation that can be observed in PD patient brains and that have been discussed to potentially be a stage in the formation of LBs (e.g., see ref. <sup><xref ref-type="bibr" rid="CR124">124</xref></sup>).</p><p id="Par18">It should also be noted that the genetics of &#x003b1;S mutations per se suggest that two ways of LB formation may exist (recently reviewed in ref. <sup><xref ref-type="bibr" rid="CR50">50</xref></sup>): one via excess membrane binding of monomers (E46K, A53T) and one via excess accumulation of soluble monomers in the cytosol (A30P, G51D). Both pathways seem to have in common the accumulation of monomers at the expense of putative physiological multimers.<sup><xref ref-type="bibr" rid="CR59">59</xref></sup></p><p id="Par19">Our final figure (Fig. <xref rid="Fig6" ref-type="fig">6</xref>) summarizes the potential pathways leading to membrane-associated and fibrillar &#x003b1;S aggregation we have emphasized in this review; the bidirectional aspects of the interplay are highlighted. In the final analysis, lipid homeostasis appears to loom ever larger in the fundamental mechanisms of human synucleinopathies.<fig id="Fig6"><label>Fig. 6</label><caption><title>&#x003b1;S/lipid homeostasis and dyshomeostasis.</title><p>Left: cell with LDs, vesicles, ER, nucleus, mitochondria and annotated with some of the lipid species discussed in this review and relevant to PD. Parts are adapted from Van Meer et al.<sup><xref ref-type="bibr" rid="CR104">104</xref></sup> Cer ceramide, Chol cholesterol, PC phosphotidylcholine, PE phosphotidylethanolamine, PI phosphatidylinositol, PS phosphotidylserine, SM sphingomyelin, TG triglyceride. Middle: intact &#x003b1;S/lipid homeostasis (top: &#x003b1;S transiently binds to membranes and undergoes cycles of assembly and disassembly) and &#x003b1;S lipid dyshomeostasis (bottom: &#x003b1;S accumulates at membranes of altered composition). Right: &#x003b1;S in disequilibrium forms fibrillar (top) or membranous non-fibrillar aggregates, mediated by abnormal lipid interactions.</p></caption><graphic xlink:href="41531_2019_103_Fig6_HTML" id="d29e1182"/></fig></p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We are grateful to Nicole Boucher, Gina Dove, and Renee Brathwaite for administrative support. The &#x003b1;S-related work of our groups is supported by NIH grants NS099328 (to U.D.), NS083845 (to D.J.S.) and a grant by the Michael J. Fox Foundation (to S.F.).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>S.F., D.J.S., and U.D. wrote the article.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par20">D.J.S. is a director and consultant to Prothena Biosciences. The other authors declare no conflict of interest.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sastry</surname><given-names>PS</given-names></name></person-group><article-title>Lipids of nervous tissue: composition and metabolism</article-title><source>Prog. Lipid Res.</source><year>1985</year><volume>24</volume><fpage>69</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/0163-7827(85)90011-6</pub-id><?supplied-pmid 3916238?><pub-id pub-id-type="pmid">3916238</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St&#x000f6;ckl</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>P</given-names></name><name><surname>Wanker</surname><given-names>E</given-names></name><name><surname>Herrmann</surname><given-names>A</given-names></name></person-group><article-title>Alpha-synuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains</article-title><source>J. Mol. Biol.</source><year>2008</year><volume>375</volume><fpage>1394</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.11.051</pub-id><?supplied-pmid 18082181?><pub-id pub-id-type="pmid">18082181</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodner</surname><given-names>CR</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name><name><surname>Bax</surname><given-names>A</given-names></name></person-group><article-title>Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy</article-title><source>J. Mol. Biol.</source><year>2009</year><volume>390</volume><fpage>775</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2009.05.066</pub-id><?supplied-pmid 19481095?><pub-id pub-id-type="pmid">19481095</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodner</surname><given-names>CR</given-names></name><name><surname>Maltsev</surname><given-names>AS</given-names></name><name><surname>Dobson</surname><given-names>CM</given-names></name><name><surname>Bax</surname><given-names>A</given-names></name></person-group><article-title>Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson&#x02019;s disease revealed by solution NMR spectroscopy</article-title><source>Biochemistry</source><year>2010</year><volume>49</volume><fpage>862</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1021/bi901723p</pub-id><?supplied-pmid 20041693?><pub-id pub-id-type="pmid">20041693</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruip&#x000e9;rez</surname><given-names>V</given-names></name><name><surname>Darios</surname><given-names>F</given-names></name><name><surname>Davletov</surname><given-names>B</given-names></name></person-group><article-title>Alpha-synuclein, lipids and Parkinson&#x02019;s disease</article-title><source>Prog. Lipid Res.</source><year>2010</year><volume>49</volume><fpage>420</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1016/j.plipres.2010.05.004</pub-id><?supplied-pmid 20580911?><pub-id pub-id-type="pmid">20580911</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharon</surname><given-names>R</given-names></name><etal/></person-group><article-title>alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>9110</fpage><lpage>9115</lpage><pub-id pub-id-type="doi">10.1073/pnas.171300598</pub-id><?supplied-pmid 11481478?><pub-id pub-id-type="pmid">11481478</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharon</surname><given-names>R</given-names></name><etal/></person-group><article-title>The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson&#x02019;s disease</article-title><source>Neuron</source><year>2003</year><volume>37</volume><fpage>583</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(03)00024-2</pub-id><?supplied-pmid 12597857?><pub-id pub-id-type="pmid">12597857</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucke</surname><given-names>C</given-names></name><name><surname>Gantz</surname><given-names>DL</given-names></name><name><surname>Klimtchuk</surname><given-names>E</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name></person-group><article-title>Interactions between fatty acids and alpha-synuclein</article-title><source>J. Lipid Res.</source><year>2006</year><volume>47</volume><fpage>1714</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1194/jlr.M600003-JLR200</pub-id><?supplied-pmid 16687662?><pub-id pub-id-type="pmid">16687662</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karube</surname><given-names>H</given-names></name><etal/></person-group><article-title>N-terminal region of alpha-synuclein is essential for the fatty acid-induced oligomerization of the molecules</article-title><source>FEBS Lett.</source><year>2008</year><volume>582</volume><fpage>3693</fpage><lpage>3700</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2008.10.001</pub-id><?supplied-pmid 18848547?><pub-id pub-id-type="pmid">18848547</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galvagnion</surname><given-names>C</given-names></name><etal/></person-group><article-title>Lipid vesicles trigger &#x003b1;-synuclein aggregation by stimulating primary nucleation</article-title><source>Nat. Chem. Biol.</source><year>2015</year><volume>11</volume><fpage>229</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1750</pub-id><?supplied-pmid 25643172?><pub-id pub-id-type="pmid">25643172</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volles</surname><given-names>MJ</given-names></name><name><surname>Lansbury</surname><given-names>PT</given-names></name></person-group><article-title>Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity</article-title><source>J. Mol. Biol.</source><year>2007</year><volume>366</volume><fpage>1510</fpage><lpage>1522</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2006.12.044</pub-id><?supplied-pmid 17222866?><pub-id pub-id-type="pmid">17222866</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dettmer</surname><given-names>U</given-names></name><etal/></person-group><article-title>Loss of native &#x003b1;-synuclein multimerization by strategically mutating its amphipathic helix causes abnormal vesicle interactions in neuronal cells</article-title><source>Hum. Mol. Genet.</source><year>2017</year><volume>26</volume><fpage>3466</fpage><lpage>3481</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddx227</pub-id><?supplied-pmid 28911198?><pub-id pub-id-type="pmid">28911198</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahmoradian</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Lewy pathology in Parkinson&#x02019;s disease consists of crowded organelles and lipid membranes</article-title><source>Nat. Neurosci.</source><year>2019</year><volume>22</volume><fpage>1099</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1038/s41593-019-0423-2</pub-id><?supplied-pmid 31235907?><pub-id pub-id-type="pmid">31235907</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanning</surname><given-names>Saranna</given-names></name><name><surname>Haque</surname><given-names>Aftabul</given-names></name><name><surname>Imberdis</surname><given-names>Thibaut</given-names></name><name><surname>Baru</surname><given-names>Valeriya</given-names></name><name><surname>Barrasa</surname><given-names>M. Inmaculada</given-names></name><name><surname>Nuber</surname><given-names>Silke</given-names></name><name><surname>Termine</surname><given-names>Daniel</given-names></name><name><surname>Ramalingam</surname><given-names>Nagendran</given-names></name><name><surname>Ho</surname><given-names>Gary P.H.</given-names></name><name><surname>Noble</surname><given-names>Tallie</given-names></name><name><surname>Sandoe</surname><given-names>Jackson</given-names></name><name><surname>Lou</surname><given-names>Yali</given-names></name><name><surname>Landgraf</surname><given-names>Dirk</given-names></name><name><surname>Freyzon</surname><given-names>Yelena</given-names></name><name><surname>Newby</surname><given-names>Gregory</given-names></name><name><surname>Soldner</surname><given-names>Frank</given-names></name><name><surname>Terry-Kantor</surname><given-names>Elizabeth</given-names></name><name><surname>Kim</surname><given-names>Tae-Eun</given-names></name><name><surname>Hofbauer</surname><given-names>Harald F.</given-names></name><name><surname>Becuwe</surname><given-names>Michel</given-names></name><name><surname>Jaenisch</surname><given-names>Rudolf</given-names></name><name><surname>Pincus</surname><given-names>David</given-names></name><name><surname>Clish</surname><given-names>Clary B.</given-names></name><name><surname>Walther</surname><given-names>Tobias C.</given-names></name><name><surname>Farese</surname><given-names>Robert V.</given-names></name><name><surname>Srinivasan</surname><given-names>Supriya</given-names></name><name><surname>Welte</surname><given-names>Michael A.</given-names></name><name><surname>Kohlwein</surname><given-names>Sepp D.</given-names></name><name><surname>Dettmer</surname><given-names>Ulf</given-names></name><name><surname>Lindquist</surname><given-names>Susan</given-names></name><name><surname>Selkoe</surname><given-names>Dennis</given-names></name></person-group><article-title>Lipidomic Analysis of &#x003b1;-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment</article-title><source>Molecular Cell</source><year>2019</year><volume>73</volume><issue>5</issue><fpage>1001-1014.e8</fpage><pub-id pub-id-type="doi">10.1016/j.molcel.2018.11.028</pub-id><?supplied-pmid 30527540?><pub-id pub-id-type="pmid">30527540</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Inhibiting stearoyl-CoA desaturase ameliorates &#x003b1;-synuclein cytotoxicity</article-title><source>Cell Rep.</source><year>2018</year><volume>25</volume><fpage>2742</fpage><lpage>2754.e31</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.11.028</pub-id><?supplied-pmid 30517862?><pub-id pub-id-type="pmid">30517862</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imberdis</surname><given-names>Thibaut</given-names></name><name><surname>Negri</surname><given-names>Joseph</given-names></name><name><surname>Ramalingam</surname><given-names>Nagendran</given-names></name><name><surname>Terry-Kantor</surname><given-names>Elizabeth</given-names></name><name><surname>Ho</surname><given-names>Gary P. H.</given-names></name><name><surname>Fanning</surname><given-names>Saranna</given-names></name><name><surname>Stirtz</surname><given-names>Georgia</given-names></name><name><surname>Kim</surname><given-names>Tae-Eun</given-names></name><name><surname>Levy</surname><given-names>Oren A.</given-names></name><name><surname>Young-Pearse</surname><given-names>Tracy L.</given-names></name><name><surname>Selkoe</surname><given-names>Dennis</given-names></name><name><surname>Dettmer</surname><given-names>Ulf</given-names></name></person-group><article-title>Cell models of lipid-rich &#x003b1;-synuclein aggregation validate known modifiers of &#x003b1;-synuclein biology and identify stearoyl-CoA desaturase</article-title><source>Proceedings of the National Academy of Sciences</source><year>2019</year><volume>116</volume><issue>41</issue><fpage>20760</fpage><lpage>20769</lpage><pub-id pub-id-type="doi">10.1073/pnas.1903216116</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon-Sanchez</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genome-wide association study reveals genetic risk underlying Parkinson&#x02019;s disease</article-title><source>Nat. Genet.</source><year>2009</year><volume>41</volume><fpage>1308</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1038/ng.487</pub-id><?supplied-pmid 19915575?><pub-id pub-id-type="pmid">19915575</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aharon-Peretz</surname><given-names>J</given-names></name><name><surname>Rosenbaum</surname><given-names>H</given-names></name><name><surname>Gershoni-Baruch</surname><given-names>R</given-names></name></person-group><article-title>Mutations in the glucocerebrosidase gene and Parkinson&#x02019;s disease in Ashkenazi Jews</article-title><source>N. Engl. J. Med.</source><year>2004</year><volume>351</volume><fpage>1972</fpage><lpage>1977</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa033277</pub-id><?supplied-pmid 15525722?><pub-id pub-id-type="pmid">15525722</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goker-Alpan</surname><given-names>O</given-names></name><etal/></person-group><article-title>Glucocerebrosidase mutations are an important risk factor for Lewy body disorders</article-title><source>Neurology</source><year>2006</year><volume>67</volume><fpage>908</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000230215.41296.18</pub-id><?supplied-pmid 16790605?><pub-id pub-id-type="pmid">16790605</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>LN</given-names></name><etal/></person-group><article-title>Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease</article-title><source>Neurology</source><year>2007</year><volume>69</volume><fpage>1270</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000276989.17578.02</pub-id><?supplied-pmid 17875915?><pub-id pub-id-type="pmid">17875915</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>WC</given-names></name><etal/></person-group><article-title>Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset</article-title><source>Neurology</source><year>2009</year><volume>72</volume><fpage>310</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000327823.81237.d1</pub-id><?supplied-pmid 18987351?><pub-id pub-id-type="pmid">18987351</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon-Sanchez</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genome-wide association study confirms extant PD risk loci among the Dutch</article-title><source>Eur. J. Hum. Genet.</source><year>2011</year><volume>19</volume><fpage>655</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2010.254</pub-id><?supplied-pmid 21248740?><pub-id pub-id-type="pmid">21248740</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Yong Ping</given-names></name><name><surname>Song</surname><given-names>Wei</given-names></name><name><surname>Huang</surname><given-names>Rui</given-names></name><name><surname>Chen</surname><given-names>Ke</given-names></name><name><surname>Zhao</surname><given-names>Bi</given-names></name><name><surname>Li</surname><given-names>Jianpeng</given-names></name><name><surname>Yang</surname><given-names>Yuan</given-names></name><name><surname>Shang</surname><given-names>Hui-Fang</given-names></name></person-group><article-title>GAK rs1564282 and DGKQ rs11248060 increase the risk for Parkinson&#x02019;s disease in a Chinese population</article-title><source>Journal of Clinical Neuroscience</source><year>2013</year><volume>20</volume><issue>6</issue><fpage>880</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1016/j.jocn.2012.07.011</pub-id><?supplied-pmid 23618683?><pub-id pub-id-type="pmid">23618683</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nalls</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x02019;s disease</article-title><source>Nat. Genet.</source><year>2014</year><volume>46</volume><fpage>989</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1038/ng.3043</pub-id><?supplied-pmid 25064009?><pub-id pub-id-type="pmid">25064009</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>XC</given-names></name><etal/></person-group><article-title>Association of Parkinson&#x02019;s disease GWAS-linked loci with Alzheimer&#x02019;s disease in Han Chinese</article-title><source>Mol. Neurobiol.</source><year>2017</year><volume>54</volume><fpage>308</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1007/s12035-015-9649-5</pub-id><?supplied-pmid 26738859?><pub-id pub-id-type="pmid">26738859</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Do</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson&#x02019;s disease</article-title><source>PLoS Genet.</source><year>2011</year><volume>7</volume><fpage>e1002141</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1002141</pub-id><?supplied-pmid 21738487?><pub-id pub-id-type="pmid">21738487</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robak</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Excessive burden of lysosomal storage disorder gene variants in Parkinson&#x02019;s disease</article-title><source>Brain J. Neurol.</source><year>2017</year><volume>140</volume><fpage>3191</fpage><lpage>3203</lpage><pub-id pub-id-type="doi">10.1093/brain/awx285</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>D</given-names></name><etal/></person-group><article-title>A meta-analysis of genome-wide association studies identifies 17 new Parkinson&#x02019;s disease risk loci</article-title><source>Nat. Genet.</source><year>2017</year><volume>49</volume><fpage>1511</fpage><lpage>1516</lpage><pub-id pub-id-type="doi">10.1038/ng.3955</pub-id><?supplied-pmid 28892059?><pub-id pub-id-type="pmid">28892059</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>JM</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Woods</surname><given-names>WS</given-names></name><name><surname>Clayton</surname><given-names>DF</given-names></name></person-group><article-title>Characterization of a novel protein regulated during the critical period for song learning in the zebra finch</article-title><source>Neuron</source><year>1995</year><volume>15</volume><fpage>361</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(95)90040-3</pub-id><?supplied-pmid 7646890?><pub-id pub-id-type="pmid">7646890</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irizarry</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system</article-title><source>J. Neuropathol. Exp. Neurol.</source><year>1996</year><volume>55</volume><fpage>889</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1097/00005072-199608000-00004</pub-id><?supplied-pmid 8759778?><pub-id pub-id-type="pmid">8759778</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahle</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model</article-title><source>Am. J. Pathol.</source><year>2001</year><volume>159</volume><fpage>2215</fpage><lpage>2225</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63072-6</pub-id><?supplied-pmid 11733371?><pub-id pub-id-type="pmid">11733371</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortin</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Lipid rafts mediate the synaptic localization of alpha-synuclein</article-title><source>J. Neurosci. J. Soc. Neurosci.</source><year>2004</year><volume>24</volume><fpage>6715</fpage><lpage>6723</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1594-04.2004</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajo</surname><given-names>S</given-names></name><name><surname>Shioda</surname><given-names>S</given-names></name><name><surname>Nakai</surname><given-names>Y</given-names></name><name><surname>Nakaya</surname><given-names>K</given-names></name></person-group><article-title>Localization of phosphoneuroprotein 14 (PNP 14) and its mRNA expression in rat brain determined by immunocytochemistry and in situ hybridization</article-title><source>Brain Res. Mol. Brain Res.</source><year>1994</year><volume>27</volume><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/0169-328X(94)90187-2</pub-id><?supplied-pmid 7877458?><pub-id pub-id-type="pmid">7877458</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortin</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Neural activity controls the synaptic accumulation of alpha-synuclein</article-title><source>J. Neurosci. J. Soc. Neurosci.</source><year>2005</year><volume>25</volume><fpage>10913</fpage><lpage>10921</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2922-05.2005</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maroteaux</surname><given-names>L</given-names></name><name><surname>Scheller</surname><given-names>RH</given-names></name></person-group><article-title>The rat brain synucleins; family of proteins transiently associated with neuronal membrane</article-title><source>Brain Res. Mol. Brain Res.</source><year>1991</year><volume>11</volume><fpage>335</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/0169-328X(91)90043-W</pub-id><?supplied-pmid 1661825?><pub-id pub-id-type="pmid">1661825</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alderson</surname><given-names>TR</given-names></name><name><surname>Markley</surname><given-names>JL</given-names></name></person-group><article-title>Biophysical characterization of &#x003b1;-synuclein and its controversial structure</article-title><source>Intrinsically Disord. Proteins</source><year>2013</year><volume>1</volume><fpage>e26255</fpage><pub-id pub-id-type="doi">10.4161/idp.26255</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wietek</surname><given-names>J</given-names></name><name><surname>Haralampiev</surname><given-names>I</given-names></name><name><surname>Amoussouvi</surname><given-names>A</given-names></name><name><surname>Herrmann</surname><given-names>A</given-names></name><name><surname>St&#x000f6;ckl</surname><given-names>M</given-names></name></person-group><article-title>Membrane bound &#x003b1;-synuclein is fully embedded in the lipid bilayer while segments with higher flexibility remain</article-title><source>FEBS Lett.</source><year>2013</year><volume>587</volume><fpage>2572</fpage><lpage>2577</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2013.06.034</pub-id><?supplied-pmid 23831067?><pub-id pub-id-type="pmid">23831067</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsigelny</surname><given-names>IF</given-names></name><etal/></person-group><article-title>Role of &#x003b1;-synuclein penetration into the membrane in the mechanisms of oligomer pore formation</article-title><source>FEBS J.</source><year>2012</year><volume>279</volume><fpage>1000</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08489.x</pub-id><?supplied-pmid 22251432?><pub-id pub-id-type="pmid">22251432</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>A</given-names></name><name><surname>Brummel</surname><given-names>BE</given-names></name><name><surname>Braun</surname><given-names>AR</given-names></name><name><surname>Rhoades</surname><given-names>E</given-names></name><name><surname>Sachs</surname><given-names>JN</given-names></name></person-group><article-title>Membrane remodeling and mechanics: experiments and simulations of &#x003b1;-Synuclein</article-title><source>Biochim. Biophys. Acta</source><year>2016</year><volume>1858</volume><fpage>1594</fpage><lpage>1609</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2016.03.012</pub-id><?supplied-pmid 26972046?><pub-id pub-id-type="pmid">26972046</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>C-Y</given-names></name><name><surname>Varkey</surname><given-names>J</given-names></name><name><surname>Ambroso</surname><given-names>MR</given-names></name><name><surname>Langen</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>S</given-names></name></person-group><article-title>Hydration dynamics as an intrinsic ruler for refining protein structure at lipid membrane interfaces</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>16838</fpage><lpage>16843</lpage><pub-id pub-id-type="doi">10.1073/pnas.1307678110</pub-id><?supplied-pmid 24082088?><pub-id pub-id-type="pmid">24082088</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jao</surname><given-names>CC</given-names></name><name><surname>Hegde</surname><given-names>BG</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Haworth</surname><given-names>IS</given-names></name><name><surname>Langen</surname><given-names>R</given-names></name></person-group><article-title>Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>19666</fpage><lpage>19671</lpage><pub-id pub-id-type="doi">10.1073/pnas.0807826105</pub-id><?supplied-pmid 19066219?><pub-id pub-id-type="pmid">19066219</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfefferkorn</surname><given-names>CM</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name></person-group><article-title>Biophysics of &#x003b1;-synuclein membrane interactions</article-title><source>Biochim. Biophys. Acta</source><year>2012</year><volume>1818</volume><fpage>162</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2011.07.032</pub-id><?supplied-pmid 21819966?><pub-id pub-id-type="pmid">21819966</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Ca(2+) modulating &#x003b1;-synuclein membrane transient interactions revealed by solution NMR spectroscopy</article-title><source>Biochim. Biophys. Acta.</source><year>2014</year><volume>1838</volume><fpage>853</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2013.11.016</pub-id><?supplied-pmid 24316000?><pub-id pub-id-type="pmid">24316000</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galvagnion</surname><given-names>C</given-names></name></person-group><article-title>The role of lipids interacting with &#x003b1;-synuclein in the pathogenesis of Parkinson&#x02019;s disease</article-title><source>J. Park. Dis.</source><year>2017</year><volume>7</volume><fpage>433</fpage><lpage>450</lpage></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rovere</surname><given-names>M</given-names></name><name><surname>Sanderson</surname><given-names>JB</given-names></name><name><surname>Fonseca&#x02010;Ornelas</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>DS</given-names></name><name><surname>Bartels</surname><given-names>T</given-names></name></person-group><article-title>Refolding of helical soluble &#x003b1;-synuclein through transient interaction with lipid interfaces</article-title><source>FEBS Lett.</source><year>2018</year><volume>592</volume><fpage>1464</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.13047</pub-id><?supplied-pmid 29633780?><pub-id pub-id-type="pmid">29633780</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fecchio</surname><given-names>C</given-names></name><etal/></person-group><article-title>&#x003b1;-Synuclein and polyunsaturated fatty acids: molecular basis of the interaction and implication in neurodegeneration</article-title><source>Molecules</source><year>2018</year><volume>23</volume><fpage>1531</fpage><pub-id pub-id-type="doi">10.3390/molecules23071531</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuscher</surname><given-names>B</given-names></name><etal/></person-group><article-title>Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: a thermodynamics study</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>21966</fpage><lpage>21975</lpage><pub-id pub-id-type="doi">10.1074/jbc.M401076200</pub-id><?supplied-pmid 15028717?><pub-id pub-id-type="pmid">15028717</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouberai</surname><given-names>MM</given-names></name><etal/></person-group><article-title>&#x003b1;-Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><fpage>20883</fpage><lpage>20895</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.478297</pub-id><?supplied-pmid 23740253?><pub-id pub-id-type="pmid">23740253</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Versatile structures of &#x003b1;-synuclein</article-title><source>Front. Mol. Neurosci.</source><year>2016</year><volume>9</volume><fpage>48</fpage><?supplied-pmid 27378848?><pub-id pub-id-type="pmid">27378848</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dettmer</surname><given-names>U</given-names></name></person-group><article-title>Rationally designed variants of &#x003b1;-synuclein Iilluminate its in vivo structural properties in health and disease</article-title><source>Front. Neurosci.</source><year>2018</year><volume>12</volume><fpage>623</fpage><pub-id pub-id-type="doi">10.3389/fnins.2018.00623</pub-id><?supplied-pmid 30319334?><pub-id pub-id-type="pmid">30319334</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeboah</surname><given-names>F</given-names></name><name><surname>Kim</surname><given-names>T-E</given-names></name><name><surname>Bill</surname><given-names>A</given-names></name><name><surname>Dettmer</surname><given-names>U</given-names></name></person-group><article-title>Dynamic behaviors of &#x003b1;-synuclein and tau in the cellular context: new mechanistic insights and therapeutic opportunities in neurodegeneration</article-title><source>Neurobiol. Dis.</source><year>2019</year><volume>132</volume><fpage>104543</fpage><pub-id pub-id-type="doi">10.1016/j.nbd.2019.104543</pub-id><?supplied-pmid 31351173?><pub-id pub-id-type="pmid">31351173</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartels</surname><given-names>T</given-names></name><name><surname>Choi</surname><given-names>JG</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>&#x003b1;-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation</article-title><source>Nature</source><year>2011</year><volume>477</volume><fpage>107</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1038/nature10324</pub-id><?supplied-pmid 21841800?><pub-id pub-id-type="pmid">21841800</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>A soluble &#x003b1;-synuclein construct forms a dynamic tetramer</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>17797</fpage><lpage>17802</lpage><pub-id pub-id-type="doi">10.1073/pnas.1113260108</pub-id><?supplied-pmid 22006323?><pub-id pub-id-type="pmid">22006323</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trexler</surname><given-names>AJ</given-names></name><name><surname>Rhoades</surname><given-names>E</given-names></name></person-group><article-title>N-Terminal acetylation is critical for forming &#x003b1;-helical oligomer of &#x003b1;-synuclein</article-title><source>Protein Sci. Publ. Protein Soc.</source><year>2012</year><volume>21</volume><fpage>601</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1002/pro.2056</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westphal</surname><given-names>CH</given-names></name><name><surname>Chandra</surname><given-names>SS</given-names></name></person-group><article-title>Monomeric synucleins generate membrane curvature</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><fpage>1829</fpage><lpage>1840</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.418871</pub-id><?supplied-pmid 23184946?><pub-id pub-id-type="pmid">23184946</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dettmer</surname><given-names>U</given-names></name><name><surname>Newman</surname><given-names>AJ</given-names></name><name><surname>Luth</surname><given-names>ES</given-names></name><name><surname>Bartels</surname><given-names>T</given-names></name><name><surname>Selkoe</surname><given-names>D</given-names></name></person-group><article-title>In vivo cross-linking reveals principally oligomeric forms of &#x003b1;-synuclein and &#x003b2;-synuclein in neurons and non-neural cells</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><fpage>6371</fpage><lpage>6385</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.403311</pub-id><?supplied-pmid 23319586?><pub-id pub-id-type="pmid">23319586</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurry</surname><given-names>T</given-names></name><etal/></person-group><article-title>The dynamic structure of alpha-synuclein multimers</article-title><source>J. Am. Chem. Soc.</source><year>2013</year><volume>135</volume><fpage>3865</fpage><lpage>3872</lpage><pub-id pub-id-type="doi">10.1021/ja310518p</pub-id><?supplied-pmid 23398399?><pub-id pub-id-type="pmid">23398399</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luth</surname><given-names>ES</given-names></name><name><surname>Bartels</surname><given-names>T</given-names></name><name><surname>Dettmer</surname><given-names>U</given-names></name><name><surname>Kim</surname><given-names>NC</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Purification of &#x003b1;-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity</article-title><source>Biochemistry</source><year>2015</year><volume>54</volume><fpage>279</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1021/bi501188a</pub-id><?supplied-pmid 25490121?><pub-id pub-id-type="pmid">25490121</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dettmer</surname><given-names>U</given-names></name><etal/></person-group><article-title>Parkinson-causing &#x003b1;-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>7314</fpage><pub-id pub-id-type="doi">10.1038/ncomms8314</pub-id><?supplied-pmid 26076669?><pub-id pub-id-type="pmid">26076669</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iljina</surname><given-names>M</given-names></name><etal/></person-group><article-title>Arachidonic acid mediates the formation of abundant alpha-helical multimers of alpha-synuclein</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>33928</fpage><pub-id pub-id-type="doi">10.1038/srep33928</pub-id><?supplied-pmid 27671749?><pub-id pub-id-type="pmid">27671749</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burr&#x000e9;</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>S&#x000fc;dhof</surname><given-names>TC</given-names></name></person-group><article-title>&#x003b1;-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>E4274</fpage><lpage>E4283</lpage><pub-id pub-id-type="doi">10.1073/pnas.1416598111</pub-id><?supplied-pmid 25246573?><pub-id pub-id-type="pmid">25246573</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>&#x003b1;-synuclein multimers cluster synaptic vesicles and attenuate recycling</article-title><source>Curr. Biol.</source><year>2014</year><volume>24</volume><fpage>2319</fpage><lpage>2326</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2014.08.027</pub-id><?supplied-pmid 25264250?><pub-id pub-id-type="pmid">25264250</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burr&#x000e9;</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>S&#x000fc;dhof</surname><given-names>TC</given-names></name></person-group><article-title>Definition of a Molecular Pathway Mediating &#x003b1;-Synuclein Neurotoxicity</article-title><source>J. Neurosci. J. Soc. Neurosci.</source><year>2015</year><volume>35</volume><fpage>5221</fpage><lpage>5232</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4650-14.2015</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dettmer</surname><given-names>U</given-names></name><name><surname>Newman</surname><given-names>AJ</given-names></name><name><surname>von Saucken</surname><given-names>VE</given-names></name><name><surname>Bartels</surname><given-names>T</given-names></name><name><surname>Selkoe</surname><given-names>D</given-names></name></person-group><article-title>KTKEGV repeat motifs are key mediators of normal &#x003b1;-synuclein tetramerization: their mutation causes excess monomers and neurotoxicity</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>9596</fpage><lpage>9601</lpage><pub-id pub-id-type="doi">10.1073/pnas.1505953112</pub-id><?supplied-pmid 26153422?><pub-id pub-id-type="pmid">26153422</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Alpha-synuclein in Lewy bodies</article-title><source>Nature</source><year>1997</year><volume>388</volume><fpage>839</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1038/42166</pub-id><?supplied-pmid 9278044?><pub-id pub-id-type="pmid">9278044</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Crowther</surname><given-names>RA</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name></person-group><article-title>alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson&#x02019;s disease and dementia with lewy bodies</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1998</year><volume>95</volume><fpage>6469</fpage><lpage>6473</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.11.6469</pub-id><?supplied-pmid 9600990?><pub-id pub-id-type="pmid">9600990</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soper</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Alpha-synuclein-induced aggregation of cytoplasmic vesicles in <italic>Saccharomyces cerevisiae</italic></article-title><source>Mol. Biol. Cell</source><year>2008</year><volume>19</volume><fpage>1093</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1091/mbc.e07-08-0827</pub-id><?supplied-pmid 18172022?><pub-id pub-id-type="pmid">18172022</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gitler</surname><given-names>AD</given-names></name><etal/></person-group><article-title>The Parkinson&#x02019;s disease protein alpha-synuclein disrupts cellular Rab homeostasis</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>145</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1073/pnas.0710685105</pub-id><?supplied-pmid 18162536?><pub-id pub-id-type="pmid">18162536</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson&#x02019;s models</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>324</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1126/science.1129462</pub-id><?supplied-pmid 16794039?><pub-id pub-id-type="pmid">16794039</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarosz</surname><given-names>DF</given-names></name><name><surname>Khurana</surname><given-names>V</given-names></name></person-group><article-title>Specification of physiologic and disease states by distinct proteins and protein conformations</article-title><source>Cell</source><year>2017</year><volume>171</volume><fpage>1001</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.10.047</pub-id><?supplied-pmid 29149602?><pub-id pub-id-type="pmid">29149602</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenreiro</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson&#x02019;s disease</article-title><source>PLoS Genet.</source><year>2014</year><volume>10</volume><fpage>e1004302</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1004302</pub-id><?supplied-pmid 24810576?><pub-id pub-id-type="pmid">24810576</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Identification and rescue of &#x003b1;-synuclein toxicity in Parkinson patient-derived neurons</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>983</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1126/science.1245296</pub-id><?supplied-pmid 24158904?><pub-id pub-id-type="pmid">24158904</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Wolman</surname><given-names>L</given-names></name></person-group><article-title>Ultrastructural observations in Parkinsonism</article-title><source>J. Pathol.</source><year>1969</year><volume>99</volume><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1002/path.1710990106</pub-id><?supplied-pmid 5359222?><pub-id pub-id-type="pmid">5359222</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forno</surname><given-names>LS</given-names></name><name><surname>Norville</surname><given-names>RL</given-names></name></person-group><article-title>Ultrastructure of Lewy bodies in the stellate ganglion</article-title><source>Acta Neuropathol. (Berl.)</source><year>1976</year><volume>34</volume><fpage>183</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1007/BF00688674</pub-id><pub-id pub-id-type="pmid">178142</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques</article-title><source>Acta Neuropathol. (Berl.)</source><year>1989</year><volume>78</volume><fpage>572</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1007/BF00691284</pub-id><pub-id pub-id-type="pmid">2683563</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashida</surname><given-names>K</given-names></name><name><surname>Oyanagi</surname><given-names>S</given-names></name><name><surname>Mizutani</surname><given-names>Y</given-names></name><name><surname>Yokochi</surname><given-names>M</given-names></name></person-group><article-title>An early cytoplasmic change before Lewy body maturation: an ultrastructural study of the substantia nigra from an autopsy case of juvenile parkinsonism</article-title><source>Acta Neuropathol. (Berl.)</source><year>1993</year><volume>85</volume><fpage>445</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1007/BF00334457</pub-id><pub-id pub-id-type="pmid">8480516</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>M</given-names></name><etal/></person-group><article-title>Synaptophysin and chromogranin A immunoreactivities of Lewy bodies in Parkinson&#x02019;s disease brains</article-title><source>Brain Res.</source><year>1994</year><volume>634</volume><fpage>339</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(94)91940-2</pub-id><?supplied-pmid 8131084?><pub-id pub-id-type="pmid">8131084</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><etal/></person-group><article-title>Staging of brain pathology related to sporadic Parkinson&#x02019;s disease</article-title><source>Neurobiol. Aging</source><year>2003</year><volume>24</volume><fpage>197</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(02)00065-9</pub-id><pub-id pub-id-type="pmid">12498954</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartels</surname><given-names>T</given-names></name></person-group><article-title>A traffic jam leads to Lewy bodies</article-title><source>Nat. Neurosci.</source><year>2019</year><volume>22</volume><fpage>1043</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1038/s41593-019-0435-y</pub-id><?supplied-pmid 31235905?><pub-id pub-id-type="pmid">31235905</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burr&#x000e9;</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>S&#x000fc;dhof</surname><given-names>TC</given-names></name></person-group><article-title>Systematic mutagenesis of &#x003b1;-synuclein reveals distinct sequence requirements for physiological and pathological activities</article-title><source>J. Neurosci. J. Soc. Neurosci.</source><year>2012</year><volume>32</volume><fpage>15227</fpage><lpage>15242</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3545-12.2012</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000e1;zaro</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation</article-title><source>PLoS Genet.</source><year>2014</year><volume>10</volume><fpage>e1004741</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1004741</pub-id><?supplied-pmid 25393002?><pub-id pub-id-type="pmid">25393002</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Outeiro</surname><given-names>TF</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name></person-group><article-title>Yeast cells provide insight into alpha-synuclein biology and pathobiology</article-title><source>Science</source><year>2003</year><volume>302</volume><fpage>1772</fpage><lpage>1775</lpage><pub-id pub-id-type="doi">10.1126/science.1090439</pub-id><?supplied-pmid 14657500?><pub-id pub-id-type="pmid">14657500</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendor</surname><given-names>JT</given-names></name><name><surname>Logan</surname><given-names>TP</given-names></name><name><surname>Edwards</surname><given-names>RH</given-names></name></person-group><article-title>The function of &#x003b1;-synuclein</article-title><source>Neuron</source><year>2013</year><volume>79</volume><fpage>1044</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.09.004</pub-id><?supplied-pmid 24050397?><pub-id pub-id-type="pmid">24050397</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sulzer</surname><given-names>D</given-names></name><name><surname>Edwards</surname><given-names>RH</given-names></name></person-group><article-title>The physiological role of &#x003b1;-synuclein and its relationship to Parkinson&#x02019;s Disease</article-title><source>J. Neurochem.</source><year>2019</year><volume>150</volume><fpage>475</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1111/jnc.14810</pub-id><?supplied-pmid 31269263?><pub-id pub-id-type="pmid">31269263</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>NB</given-names></name><etal/></person-group><article-title>Lipid droplet binding and oligomerization properties of the Parkinson&#x02019;s disease protein alpha-synuclein</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>6344</fpage><lpage>6352</lpage><pub-id pub-id-type="doi">10.1074/jbc.M108414200</pub-id><?supplied-pmid 11744721?><pub-id pub-id-type="pmid">11744721</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abeliovich</surname><given-names>A</given-names></name><name><surname>Gitler</surname><given-names>AD</given-names></name></person-group><article-title>Defects in trafficking bridge Parkinson&#x02019;s disease pathology and genetics</article-title><source>Nature</source><year>2016</year><volume>539</volume><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/nature20414</pub-id><?supplied-pmid 27830778?><pub-id pub-id-type="pmid">27830778</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzulli</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Gaucher disease glucocerebrosidase and &#x003b1;-synuclein form a bidirectional pathogenic loop in synucleinopathies</article-title><source>Cell</source><year>2011</year><volume>146</volume><fpage>37</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.06.001</pub-id><?supplied-pmid 21700325?><pub-id pub-id-type="pmid">21700325</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auluck</surname><given-names>PK</given-names></name><name><surname>Caraveo</surname><given-names>G</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name></person-group><article-title>alpha-Synuclein: membrane interactions and toxicity in Parkinson&#x02019;s disease</article-title><source>Annu Rev. Cell Dev. Biol.</source><year>2010</year><volume>26</volume><fpage>211</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.042308.113313</pub-id><?supplied-pmid 20500090?><pub-id pub-id-type="pmid">20500090</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klemann</surname><given-names>C</given-names></name><etal/></person-group><article-title>Integrated molecular landscape of Parkinson&#x02019;s disease</article-title><source>NPJ Park. Dis.</source><year>2017</year><volume>3</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1038/s41531-017-0015-3</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><etal/></person-group><article-title>Association of GALC, ZNF184, IL1R2 and ELOVL7 With Parkinson&#x02019;s disease in Southern Chinese</article-title><source>Front. Aging Neurosci.</source><year>2018</year><volume>10</volume><fpage>402</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2018.00402</pub-id><?supplied-pmid 30618709?><pub-id pub-id-type="pmid">30618709</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>NV</given-names></name><etal/></person-group><article-title>PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron</article-title><source>Nat. Genet.</source><year>2006</year><volume>38</volume><fpage>752</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1038/ng1826</pub-id><?supplied-pmid 16783378?><pub-id pub-id-type="pmid">16783378</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Goodman</surname><given-names>JM</given-names></name></person-group><article-title>The collaborative work of droplet assembly</article-title><source>Biochim. Biophys. Acta</source><year>2017</year><volume>1862</volume><fpage>1205</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2017.07.003</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walther</surname><given-names>Tobias C.</given-names></name><name><surname>Chung</surname><given-names>Jeeyun</given-names></name><name><surname>Farese</surname><given-names>Robert V.</given-names></name></person-group><article-title>Lipid Droplet Biogenesis</article-title><source>Annual Review of Cell and Developmental Biology</source><year>2017</year><volume>33</volume><issue>1</issue><fpage>491</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-100616-060608</pub-id><?supplied-pmid 28793795?><pub-id pub-id-type="pmid">28793795</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dijk</surname><given-names>KD</given-names></name><etal/></person-group><article-title>The proteome of the locus ceruleus in Parkinson&#x02019;s disease: relevance to pathogenesis</article-title><source>Brain Pathol.</source><year>2012</year><volume>22</volume><fpage>485</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2011.00540.x</pub-id><?supplied-pmid 21988495?><pub-id pub-id-type="pmid">21988495</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Licker</surname><given-names>V</given-names></name><etal/></person-group><article-title>Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson&#x02019;s disease pathogenesis</article-title><source>Proteomics</source><year>2014</year><volume>14</volume><fpage>784</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1002/pmic.201300342</pub-id><?supplied-pmid 24449343?><pub-id pub-id-type="pmid">24449343</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quadri</surname><given-names>M</given-names></name><etal/></person-group><article-title>LRP10 genetic variants in familial Parkinson&#x02019;s disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study</article-title><source>Lancet Neurol.</source><year>2018</year><volume>17</volume><fpage>597</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(18)30179-0</pub-id><?supplied-pmid 29887161?><pub-id pub-id-type="pmid">29887161</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergouw</surname><given-names>LJM</given-names></name><etal/></person-group><article-title>LRP10 variants in Parkinson&#x02019;s disease and dementia with Lewy bodies in the South-West of the Netherlands</article-title><source>Parkinsonism Relat. Disord.</source><year>2019</year><volume>65</volume><fpage>243</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2019.05.037</pub-id><?supplied-pmid 31147221?><pub-id pub-id-type="pmid">31147221</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>LRP10 in autosomal-dominant Parkinson&#x02019;s disease</article-title><source>Mov. Disord. J. Mov. Disord. Soc.</source><year>2019</year><volume>34</volume><fpage>912</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1002/mds.27693</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodeur</surname><given-names>J</given-names></name><etal/></person-group><article-title>LDLR-related protein 10 (LRP10) regulates amyloid precursor protein (APP) trafficking and processing: evidence for a role in Alzheimer&#x02019;s disease</article-title><source>Mol. Neurodegener.</source><year>2012</year><volume>7</volume><fpage>31</fpage><pub-id pub-id-type="doi">10.1186/1750-1326-7-31</pub-id><?supplied-pmid 22734645?><pub-id pub-id-type="pmid">22734645</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzulli</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Activation of &#x003b2;-glucocerebrosidase reduces pathological &#x003b1;-synuclein and restores lysosomal function in Parkinson&#x02019;s patient midbrain neurons</article-title><source>J. Neurosci. J. Soc. Neurosci.</source><year>2016</year><volume>36</volume><fpage>7693</fpage><lpage>7706</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0628-16.2016</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><etal/></person-group><article-title>GBA1 deficiency negatively affects physiological &#x003b1;-synuclein tetramers and related multimers</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>798</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1073/pnas.1700465115</pub-id><?supplied-pmid 29311330?><pub-id pub-id-type="pmid">29311330</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brekk</surname><given-names>OR</given-names></name><name><surname>Moskites</surname><given-names>A</given-names></name><name><surname>Isacson</surname><given-names>O</given-names></name><name><surname>Hallett</surname><given-names>PJ</given-names></name></person-group><article-title>Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>15207</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-33474-z</pub-id><?supplied-pmid 30315256?><pub-id pub-id-type="pmid">30315256</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>MS</given-names></name><name><surname>Bongarzone</surname><given-names>ER</given-names></name></person-group><article-title>Beyond Krabbe&#x02019;s disease: The potential contribution of galactosylceramidase deficiency to neuronal vulnerability in late-onset synucleinopathies</article-title><source>J. Neurosci. Res.</source><year>2016</year><volume>94</volume><fpage>1328</fpage><lpage>1332</lpage><pub-id pub-id-type="doi">10.1002/jnr.23751</pub-id><?supplied-pmid 27638614?><pub-id pub-id-type="pmid">27638614</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Meer</surname><given-names>G</given-names></name><name><surname>Voelker</surname><given-names>DR</given-names></name><name><surname>Feigenson</surname><given-names>GW</given-names></name></person-group><article-title>Membrane lipids: where they are and how they behave</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2008</year><volume>9</volume><fpage>112</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/nrm2330</pub-id><?supplied-pmid 18216768?><pub-id pub-id-type="pmid">18216768</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>PL</given-names></name><name><surname>Tippireddy</surname><given-names>S</given-names></name><name><surname>Feriante</surname><given-names>J</given-names></name><name><surname>Woltjer</surname><given-names>RL</given-names></name></person-group><article-title>Augmented frontal cortex diacylglycerol levels in Parkinson&#x02019;s disease and Lewy body disease</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><fpage>e0191815</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0191815</pub-id><?supplied-pmid 29513680?><pub-id pub-id-type="pmid">29513680</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>D</given-names></name><etal/></person-group><article-title>Lipid pathway alterations in Parkinson&#x02019;s disease primary visual cortex</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><fpage>e17299</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0017299</pub-id><?supplied-pmid 21387008?><pub-id pub-id-type="pmid">21387008</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoessel</surname><given-names>D</given-names></name><etal/></person-group><article-title>Promising mmetabolite profiles in the plasma and CSF of early clinical Parkinson&#x02019;s disease</article-title><source>Front. Aging Neurosci.</source><year>2018</year><volume>10</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2018.00051</pub-id><?supplied-pmid 29556190?><pub-id pub-id-type="pmid">29556190</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farmer</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>CA</given-names></name><name><surname>Hayley</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name></person-group><article-title>Major Alterations of phosphatidylcholine and lysophosphotidylcholine lipids in the substantia nigra using an early stage model of Parkinson&#x02019;s disease</article-title><source>Int. J. Mol. Sci.</source><year>2015</year><volume>16</volume><fpage>18865</fpage><lpage>18877</lpage><pub-id pub-id-type="doi">10.3390/ijms160818865</pub-id><?supplied-pmid 26274953?><pub-id pub-id-type="pmid">26274953</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seyfried</surname><given-names>TN</given-names></name><etal/></person-group><article-title>Sex-related abnormalities in substantia nigra lipids in Parkinson&#x02019;s disease</article-title><source>ASN Neuro</source><year>2018</year><volume>10</volume><fpage>1759091418781889</fpage><pub-id pub-id-type="doi">10.1177/1759091418781889</pub-id><?supplied-pmid 29932343?><pub-id pub-id-type="pmid">29932343</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Leary</surname><given-names>EI</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Strub</surname><given-names>M-P</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name></person-group><article-title>Effects of phosphatidylcholine membrane fluidity on the conformation and aggregation of N-terminally acetylated &#x003b1;-synuclein</article-title><source>J. Biol. Chem.</source><year>2018</year><volume>293</volume><fpage>11195</fpage><lpage>11205</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.002780</pub-id><?supplied-pmid 29853639?><pub-id pub-id-type="pmid">29853639</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>D</given-names></name><name><surname>Witt</surname><given-names>SN</given-names></name></person-group><article-title>Ethanolamine and phosphatidylethanolamine: partners in health and disease</article-title><source>Oxid. Med. Cell. Longev.</source><year>2017</year><volume>2017</volume><fpage>4829180</fpage><pub-id pub-id-type="doi">10.1155/2017/4829180</pub-id><?supplied-pmid 28785375?><pub-id pub-id-type="pmid">28785375</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vance</surname><given-names>JE</given-names></name></person-group><article-title>Phosphotidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids</article-title><source>J. Lipid Res.</source><year>2008</year><volume>49</volume><fpage>1377</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1194/jlr.R700020-JLR200</pub-id><?supplied-pmid 18204094?><pub-id pub-id-type="pmid">18204094</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattingen</surname><given-names>E</given-names></name><etal/></person-group><article-title>Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson&#x02019;s disease</article-title><source>Brain J. Neurol.</source><year>2009</year><volume>132</volume><fpage>3285</fpage><lpage>3297</lpage><pub-id pub-id-type="doi">10.1093/brain/awp293</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phosphatidylethanolamine deficiency disrupts &#x003b1;-synuclein homeostasis in yeast and worm models of Parkinson disease</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>E3976</fpage><lpage>E3985</lpage><pub-id pub-id-type="doi">10.1073/pnas.1411694111</pub-id><?supplied-pmid 25201965?><pub-id pub-id-type="pmid">25201965</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witt</surname><given-names>SN</given-names></name></person-group><article-title>Lipid disequilibrium in biological membranes, a possible pathway to neurodegeneration</article-title><source>Commun. Integr. Biol.</source><year>2014</year><volume>7</volume><fpage>e993266</fpage><pub-id pub-id-type="doi">10.4161/19420889.2014.993266</pub-id><?supplied-pmid 26480301?><pub-id pub-id-type="pmid">26480301</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comprehensive analysis of phospholipids in the brain, heart, kidney, and liver: brain phospholipids are least enriched with polyunsaturated fatty acids</article-title><source>Mol. Cell. Biochem.</source><year>2018</year><volume>442</volume><fpage>187</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1007/s11010-017-3203-x</pub-id><?supplied-pmid 28993959?><pub-id pub-id-type="pmid">28993959</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rappley</surname><given-names>I</given-names></name><etal/></person-group><article-title>Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype</article-title><source>J. Neurochem.</source><year>2009</year><volume>111</volume><fpage>15</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06290.x</pub-id><?supplied-pmid 19627450?><pub-id pub-id-type="pmid">19627450</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>BM</given-names></name><name><surname>Mamalias</surname><given-names>N</given-names></name><name><surname>Moszczynska</surname><given-names>A</given-names></name><name><surname>Rajput</surname><given-names>AH</given-names></name><name><surname>Kish</surname><given-names>SJ</given-names></name></person-group><article-title>Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson&#x02019;s disease</article-title><source>Neuroscience</source><year>2001</year><volume>102</volume><fpage>899</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(00)00501-7</pub-id><?supplied-pmid 11182251?><pub-id pub-id-type="pmid">11182251</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Hawk</surname><given-names>BJ</given-names></name><name><surname>Shin</surname><given-names>Y-K</given-names></name></person-group><article-title>&#x003b1;-Synuclein may cross-bridge v-SNARE and acidic phospholipids to facilitate SNARE-dependent vesicle docking</article-title><source>Biochem. J.</source><year>2017</year><volume>474</volume><fpage>2039</fpage><lpage>2049</lpage><pub-id pub-id-type="doi">10.1042/BCJ20170200</pub-id><?supplied-pmid 28495859?><pub-id pub-id-type="pmid">28495859</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabelo</surname><given-names>N</given-names></name><etal/></person-group><article-title>Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson&#x02019;s disease and incidental Parkinson&#x02019;s disease</article-title><source>Mol. Med. Camb. Mass.</source><year>2011</year><volume>17</volume><fpage>1107</fpage><lpage>1118</lpage><?supplied-pmid 21717034?><pub-id pub-id-type="pmid">21717034</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volpicelli-Daley</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Exogenous &#x003b1;-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death</article-title><source>Neuron</source><year>2011</year><volume>72</volume><fpage>57</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.08.033</pub-id><?supplied-pmid 21982369?><pub-id pub-id-type="pmid">21982369</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luk</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Intracerebral inoculation of pathological &#x003b1;-synuclein initiates a rapidly progressive neurodegenerative &#x003b1;-synucleinopathy in mice</article-title><source>J. Exp. Med.</source><year>2012</year><volume>209</volume><fpage>975</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1084/jem.20112457</pub-id><?supplied-pmid 22508839?><pub-id pub-id-type="pmid">22508839</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuber</surname><given-names>S</given-names></name><etal/></person-group><article-title>Abrogating native &#x003b1;-synuclein tetramers in mice causes a L-DOPA-responsive motor syndrome closely resembling Parkinson&#x02019;s disease</article-title><source>Neuron</source><year>2018</year><volume>100</volume><fpage>75</fpage><lpage>90.e5</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.09.014</pub-id><?supplied-pmid 30308173?><pub-id pub-id-type="pmid">30308173</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dale</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Relationships between Lewy bodies and pale bodies in Parkinson&#x02019;s disease</article-title><source>Acta Neuropathol. (Berl.)</source><year>1992</year><volume>83</volume><fpage>525</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1007/BF00310030</pub-id><pub-id pub-id-type="pmid">1320323</pub-id></element-citation></ref></ref-list></back></article>